Celator(R) Pharmaceuticals Announces New Data for VYXEOS(TM) in FLT3-ITD Mutated AML Cells Derived from Patients with Newly Diagnosed AML to be Presented at the American Association for Cancer Research Annual Meeting
March 31, 2016Celator Pharmaceuticals, Inc. today announced that data for VYXEOS™ Liposome for Injection will be presented at the American Association for Cancer Research (AACR) Annual Meeting.
More »
Celator(R) Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2015 Financial Results
March 21, 2016Ended year with $23.3 million cash and cash equivalents; additional $9.8 million net proceeds raised in first quarter 2016 now provides sufficient cash into the second quarter of 2017
More »
New Data Show That Veracyte’s Afirma® Gene Expression Classifier Reduces Unnecessary Thyroid Surgeries and Costs During Long-Term Follow-Up
March 16, 2016New Data Show That Veracyte’s Afirma® Gene Expression Classifier Reduces Unnecessary Thyroid Surgeries and Costs During Long-Term Follow-Up
More »